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ABSTRACT 
Purpose/Aim of the Study: Adenosine signaling was studied in bronchiolitis obliterans organizing pneumonia 
(BOOP) resulting from unilateral lung ischemia. Materials and Methods: Ischemia was achieved by either left 
main pulmonary artery or complete hilar ligation. Sprague–Dawley (SD) rats, Dahl salt sensitive (SS) rats and SS 
mutant rat strains containing a mutation in the A2B adenosine receptor gene (Adora2b)were studied. Adenosine 
concentrationswere measured in bronchoalveolar lavage (BAL) by HPLC. A2A (A2AAR) and A2B adenosine 
receptor (A2BAR) mRNA and protein were quantified. Results: Twenty-four hours after unilateral PA ligation, 
BAL adenosine concentrations from ischemic lungs were increased relative to contralateral lungs in SD rats. 
A2BAR mRNA and protein concentrations were increased after PA ligation while miR27a, a negatively 
regulatingmicroRNA, was decreased in ischemic lungs. A2AAR mRNA and protein concentrations remained 
unchanged following ischemia. A2BAR protein was increased in PA ligated lungs of SS rats after 7 days, and 4 h 
after complete hilar ligation in SD rats. SS-Adora2b mutants showed a greater extent of BOOP relative to SS rats, 
and greater inflammatory changes. Conclusion: IncreasedA2BAR and adenosine following unilateral lung 
ischemia as well as more BOOP in A2BAR mutant rats implicate a protective role for A2BAR signaling in coun  
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A2B adenosine receptor; bronchiolitis obliterans organizing pneumonia; lung ischemia; lung transplanttering 
ischemic lung injury. 
Introduction 
Lung transplantation is the final option for patients suffering from end-stage lung disease. The efficacy of 2000 
yearly transplants in the United States is severely limited by graft availability, preoperative function, and a 50% 
postoperative failure rate within 5 years.[ 1]Bronchiolitis obliterans (BO), a pathologic condition in which small 
airways become irreversibly obstructed by granulation tissue and fibrosis, is the major cause of morbidity and 
mortality resulting from lung transplantation.[ 1], [ 2] As a harbinger of BO, bronchiolitis obliterans organizing 
pneumonia (BOOP) occurs early postoperatively (weeks to months) and is associated with a doubled risk of 
subsequent BO and graft failure.[ 3], [ 4] Ischemia/reperfusion (I/R) is a major risk factor for all post-transplant 
problems, including BOOP.[ 5] In order to detect and understand the early ischemic mechanisms inducing BOOP, 
we developed a rat model of unilateral lung ischemia whereby the left pulmonary artery is ligated in situ. This 
provides a contralateral control lung for comparison. This model completely avoids immunomodulation and 
maintains ventilation to both lungs.[ 6] In the present work, we explore the role of adenosine signaling in this 
injury response. 
Pulmonary I/R increases adenosine production, with some studies reporting a proinflammatory role for 
A2B adenosine receptor (A2BAR) engagement in the transplanted lung.[ 7], [ 8], [ 9] However, others describe 
A2BAR conferring protection against lipopolysaccharide- or mechanical ventilation-induced direct lung 
injury.[10], [11], [12] The goal of this study was to examine the role of A2BAR signaling promoting postischemic 
BOOP. The studies presented utilize a novel rat A2BAR mutant, A2BAR mRNA lung levels, A2BAR lung protein 
expression, and translation-regulating miRNA lung levels to correlate A2BAR function with histopathologic 
changes seen in ischemic BOOP. We report data from three strains of rats, including Sprague Dawley rats, an 
A2BAR mutant, and the background strain for the A2b mutant, SS rats. These three strains permit conclusions 
regarding the role of A2b receptors in rodents with two significantly different genetic backgrounds, thus 
enhancing the translational implications to humans with widely variable genetic makeups. 
There are currently three known miRNA sequences that regulate A2BAR expression: miR27b, miR128a, and 
miR128b. [13], [14], [15] All three have been implicated in A2BAR in vitro signaling (e.g., B-lymphocyte 
differentiation and 3T3-PKD-1 cell differentiation).[13], [15] Given the negative regulation of A2BAR in murine 
colitis, we focused upon the role of miR27b and miR128a in this model.[14] 
Our data provide evidence that adenosine release and activation of A2BARs are protective responses that limit 
the development of BOOP, and hence BO. 
Materials and methods 
antibodies for A2AAR and A2BAR were purchased from Alomone labs (A2BAR Cat# AAR-003, A2AAR Cat# AAR-002). 
Adenosine for standards was obtained from Sigma (Cat#A9251). β-actin antibody was also obtained from Sigma 
(Cat#A2228). 
Sequence specific primers for miRNA were obtained from Exiqon. Target sequences follow: 
• miR-128-3p: UCACAGUGAACCGGUCUCUUU Product# 205677 
• miR-27a-3p: UUCACAGUGGCUAAGUUCCGC Product#204764 
• miR-27b-3p: UUCACAGUGGCUAAGUUCUGC Product# 204782 
• miR-191a-5p: CAACGGAAUCCCAAAAGCAGCUG Product #204306). 
• mRNA primers were obtained from Integrated DNA Technology with following sequences: 
• A2BAR forward: GCGGCACCTTAGCGGCTGTC (Product#117239370) 
• A2BAR reverse: TACCTGAGCGGGACGCGAAT (Product#117239371) 
• A2AAR forward: CCATGCTGGGCTGGAACA (Product# 117239368) 
• A2AAR reverse: GAAGGGGCAGTAACACGA (Product #117239369) 
 
Animal models: AdorA2b mutants. All animal procedures including the generation of the A2BAR mutant model, 
breeding, and phenotypic characterization were performed at the Medical College of Wisconsin using protocols 
approved by the Institutional Animal Care and Use Committee and in compliance with the National Research 
Council's Guide for the Care and Use of Laboratory Animals. Zinc-Finger Nuclease (ZFN) constructs specific for 
rat AdorA2BA were designed, assembled, and validated by Sigma-Aldrich, to target the sequence 
AACTACTTTCTGGTGTccctgGCGACGGCGGACGTGGCT within the first exon of AdorA2BA, where each member of 
heterodimeric ZFN pair binds to the underlined sequence on opposite strands. mRNA encoding 
the AdorA2BA ZFN was injected into SS/JrHsdMcwi (SS) rat embryos, as described previously.[16], [17] Mutant 
founders were identified using the primers A2BAR_F: ACACAACCCCGGTAGAGGA and A2BAR_R: 
GATGGAGCTCTGTGTGAGCA. 
A founder harboring genomic deletion was identified and validated by Sanger sequencing (Figure 1). A mutant 
founder was backcrossed to the parental SS strain and heterozygous animals from subsequent generations were 
intercrossed in order to generate homozygous mutant animals and were used for all reported studies. This strain 
is designated as SS-Adora2b. Parental SS rats were used as genetic background controls. 
 
Graph: Figure 1. cDNA sequence of the A2BAR highlighting the Adora2b mutation, which caused an in-frame 
deletion. The red region denotes the mutated region, which resulted in deletion of the start codon (blue). The 
next available start codon is highlighted in blue. This mutated strain is predicted to express a truncated form of 
the A2BAR lacking the amino terminus, intracellular loops 1 and 2, extracellular loops 1 and 2, and the first 4 
transmembrane segments. The green highlights indicate the primer set used for genotyping. Transmembrane 
regions are highlighted in light grey for easy identification of these areas deleted. 
Surgical procedures: Male SD (Harlan Labs), SS or A2BAR mutant rats (200–400 gm) were used for the 
experiments. To create unilateral ischemia without compromise of airflow or reperfusion, we used a left 
anterior thoracotomy to complete an occlusive slip knot tie over the left main pulmonary artery under general 
anesthesia using isoflurane (2%), as we previously reported.[ 6] In brief, the left main pulmonary artery was 
identified on the superior aspect of the left mainstem bronchus and then dissected free from the bronchus. A 6-
O suture was passed around the left main pulmonary artery and tied.[ 6] Rats were allowed to recover from 
surgery, administered carprofen (5 mg/kg b.i.d. for 3 days) for analgesia and studied 1–7 days later. 
In selected rats where indicated in the text, a second model of unilateral lung ischemia characterized by 
increased myeloperoxidase as we previously reported with PA and airway ischemia and reperfusion was 
employed.[18] A midline incision was made and the chest opened to access the left hilum. The left pulmonary 
artery, vein, and bronchus were stripped of connective tissue and then occluded with a microvascular clamp to 
induce ischemia. After 60 minutes, the clamp was removed to allow spontaneous reperfusion and reinitiation of 
lung ventilation. Lung tissue was harvested three hours after reperfusion. 
Adenosine BAL measurements: Adenosine was measured by adaptation of methods described by Driver 
et al.[19] Twenty four hours after left pulmonary artery ligation (see earlier text), Sprague–Dawley rats were 
anesthetized with 2% isoflurane, intubated, and subjected to thoracotomy via a midline incision. The heart and 
lungs were removed from the chest en block, after which the left and right lungs were lavaged separately two 
times with 3.0 mL of PBS (4°C) containing the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-
nonyl)adenine hydrochloride (EHNA, 2.5 μM) and the nucleotide transport inhibitor dipyridamole (250 μM) 
(stopping solutions). In the case of control rats, lavage fluid (5.0 mL) was collected from both lungs. BAL fluid 
was centrifuged (1000 g for 10 min at 4°C) and then passed through a 0.2 μ filter to remove cellular debris. 
To determine the range and sensitivity of our assay as well as potential sources of loss with filtration, 
centrifugation or freezing, adenosine (cat# A9251 Sigma) was added to lavage fluid from an independent group 
of control rats to final concentrations of 2, 10, and 50 μM above endogenous adenosine levels either before or 
after centrifugation and filtration. 
Briefly, an Agilent 1100 HPLC system was used and the samples (100 µL) were injected into Kinetex C18 columns 
(Phenomenex, 100 mm × 4.6 mm, 2.6 µm) equipped with a guard column and equilibrated with an aqueous 
solution of KH2PO4 (12.5 mM) containing 7.5% methanol. Isocratic elution of adenosine was achieved using the 
equilibration buffer at a flow rate of 1.4 ml/min. The retention time of adenosine was 4.2 min by UV detection at 
260 nm. Peak area at 260 nm was used for quantification. 
RNA studies: Total RNA from ∼100 mg of right and left lung tissues were extracted with Trizol reagent (Cat# 
15596-026, Invitrogen, USA), according to the manufacturer's instructions. The concentration and purity of RNA 
were determined by a Nanodrop spectrophotometer. 
QuantitativeTable 1real time PCR. Synthesis of cDNA was performed using the miRCURY LNA Universal RT 
microRNA PCR kit (Cat# 203301,Exiqon). A total of 100 ng of total RNA was used for reverse transcription with 
polyT-tagged universal primer. Briefly, the tubes were incubated for 60 min at 42°C, followed by heat-
inactivation of the reverse transcriptase enzyme for 5 min at 95°C. Real-time PCR was performed with A2AAR, 
A2BAR and GAPDH (internal control) primers using recommended annealing temperatures for each primer set 
(IDT). For miRNA, real-time PCR was performed with miR-27a-3p (cat# 204764), miR-27b-3p (cat# 204782), and 
miR-128-3p(cat# 295677) LNA primers (Exiqon), as well as SYBR Green master mix (Cat# 203403 Exiqon). MiR-
191a-5p (cat # 204306) was used as an internal control along with UniSP6 provided with the cDNA kit to account 
for efficiency of reverse transcription for miRNA analyses. PCR was carried out according to the manufacturer's 
instructions (Cat# 203301, Exiqon) using a Bio-Rad icycler (Model CFX 96 Real time system). The following cycling 
conditions were employed for miRNA: 95°C for 10 min, followed by 40 cycles of 95°C for 10 s, and 60°C for 
1 min. The expression level of mRNA in each sample was normalized to GAPDH and miRNA to either miR-191a-
5p or to UniSP6. Then, relative expression levels in right and left lung samples were calculated using the CT 
values for the RNA of interest by using 2− ΔΔCT method. 
Western immunoblotting of A2AAR and A2BAR: Western blot analysis was performed as described previously.[18] 
Briefly, whole lung homogenates in a buffer supplemented with protease inhibitor cocktail were centrifuged for 
10 min at 20,000 g. Blots were developed with a primary antibody to A2AAR, A2BAR or β-actin (Sigma #A2228) 
and matched secondary antibodies conjugated to horseradish peroxidase. ECL detection reagent (Pierce # 
32106) was used for visualization. The relative densities of protein bands were compared in images scanned 
with an Alpha Image 220 Analysis System, with β-actin used to correct for protein loading. Bands at ∼48 and 
37 kDa were observed in our immunoblots. The band just smaller than 50 kDa is consistent with immunospecific 
band identified by this Alomone antibody in rodent tissue.[20] Both bands were competed away by blocking 
peptide (Alomone Labs: www.alomone.com/p/anti-A2BA%5fadenosine%5freceptor%5f(extracellular)/aar-
003/114). The band just smaller than 50 kDa band was used for quantification as it was the most reproducible in 
our hands and was consistent with results by Vindeirinho et al.[20] 
Histology: The heart and lungs were removed en bloc under isoflurane anesthesia. Lungs were fixed with 
paraformaldehyde in the inflated state. Four-micron thick slices of paraffin-embedded, fixed whole-mount 
coronal sections of left and right lung were stained for hematoxylin and eosin. Extent of BOOP was quantified by 
assessing percentage of the cross sectional area of the lung involved at low power, morphology confirmed with 
high-resolution JPEG images, as we previously reported.[ 6] Histology consistent with BOOP (Masson bodies, 
inflammation, and young fibroblasts filling the distal airways and alveoli) was assessed with high power images. 
Using a scale developed for quantification of BOOP,[ 6], [21] we also performed grading of epithelial injury, 
fibrosis, and inflammatory changes (EFI) in the most severely affected areas of cross sectional lung images, each 
on a zero to three scale. The presence or absence of pulmonary vascular changes (thickening of intima or media 
or vascular drop out) and necrosis were noted in each image (Table 1). Two blinded reviewers graded all images. 
Average values were used for analysis. 
Table 1. To quantify BOOP, we developed a grading scale for our studies[ 6] based on methods to quantify BOOP 
in human transplant patients.[21] This scale includes grading epithelial injury, fibrosis, and inflammatory 
changes, each on a scale from zero to three, and estimation of the percentage area of the lung exhibiting BOOP. 
Images were graded by two investigators blinded to the treatment group. 
Histological 
grading of BOOP 
    
Grade 0 1 (mild) 2 (moderate) 3 (severe) 
E (epithelial) Normal Reactive epithelium 
±intermittent 
disruption of epithelial 
layer 
Moderately prevalent 
disruption and loss of 
epithelium 
Epithelium largely 
denuded 
F (fibrotic) Normal Young fibroblasts Intraluminal 
fibromyxoid filling 
Dense fibrosis 
I (inflammatory) Normal Perivascular or 
peribronchial cuffing 
with mixed 
inflammatory cells 
Moderate mixed 
inflammatory 
infiltration throughout 
the lungs 
Severe infiltration 
of mixed 
inflammatory cells 
     
Percent 
involvement 
(from 0 to 100% 
in 10% 
increments) 
 
Statistical analysis: All analyses were not performed on all rats, as some (e.g., histological analysis and RNA 
extraction) were mutually exclusive. For each assay, a minimum of four, and typically five to eight, separate rats 
were studied per group. The group size is shown in the figure legends, figures, text, or table. Comparisons 
between ischemic and nonischemic lungs were performed using t tests or rank sum tests followed by Mann–
Whitney Rank Sum test when data were not normally distributed. Grouped data for three or more conditions 
were compared using one-way analysis of variance. When differences were found, a Holm–Sidak's post hoc test 
was employed. Statistical significance was assumed for p < 0.05. All grouped data shown in figures are presented 
as means ± standard error of the mean (SEM), means ± standard deviation (SD), or medians and confidence 
intervals in the case of nonparametric data. 
Results 
Adenosine concentrations in BAL 
Representative HPLCs for quantification of adenosine concentrations appear in Figure 2a. Adenosine 
concentration values for control lungs of SD rats were not different than those from contralateral, nonischemic 
lungs from SD rats (0.89± 0.23 μM vs. 0.59 ± 0.09; n = 4 each). BAL from ischemic relative to contralateral lungs 
exhibited adenosine concentrations, which were increased approximately fourfold over those of contralateral 
lungs 24 h after PA ligation (Figure 2a and 2b). 
 
Graph: Figure 2. Adenosine concentrations were measured in BAL from four SD control rats or from isolated left 
and right lungs from four SD rats collected 24 h after left pulmonary artery ligation. Figure 2a shows 
representative chromatograms from an adenosine standard (3 μM) and from BAL collected from the right and 
left lungs of ischemic/reperfused rats. The graph in 2b shows individual values for samples. The concentration of 
adenosine was increased more than fourfold in BAL from ischemic lungs versus contralateral non-ischemic lungs 
(*p < 0.008). Horizontal lines represent median values for each of the three groups. 
Adenosine receptor mRNA and protein expression 
Next we evaluated A2AAR and A2BAR mRNA expression in ischemic versus nonischemic lungs. Message for A2B AR 
(n = 17 pairs, Mann–Whitney Rank Sum Test p = 0.03) but not A2AR (n = 13 pairs, Mann–Whitney Rank Sum 
Test p = 0.20) was increased in ischemic lungs of SD rats 7 days after tie off of the left pulmonary artery 
(Figure 3). 
  
Graph: Figure 3. Graphic representation showing GAPDH normalized expression of A2BAR and A2AAR mRNA 
from ischemic (L = left) and nonischemic (R = right) in 13 SD rats 7 days after left PA tie. The bars represent 
medians and bars show confidence intervals. A2BAR expression was greater in ischemic than nonischemic lungs 
(p = 0.03) while A2AAR was not different (p = 0.20). 
Western blots of lung homogenates from ischemic left lungs of SD rats exhibited increased anti-A2BAR 
immunoreactivity at two and seven days after unilateral ligation of the pulmonary arteries (Figures 4a and 5). 
Similarly, SS rats had increased anti-A2B AR immunoreactivity in ischemic versus contralateral non-ischemic lungs 
(Figure 4b and 5). In contrast, anti-A2AR immunoreactivity from the same rats was not different between 
ischemic and nonischemic lungs (Figure 4c; n = 9 pairs, p = 0.8). In a second lung injury model involving unilateral 
warm ischemia of the lung for one hour followed by in vivo reperfusion for three additional hours, A2BAR protein 
density normalized to beta actin was also increased in ischemic relative to contralateral lungs (n = 8 pairs; 
125±10 vs. 90±12, p < 0.05; data not shown). 
 Graph: Figure 4. 4a shows representative Western blots of homogenates from ischemic (L = left) and 
contralateral (R = right) lungs from SD rats harvested either 2 or 7 days after pulmonary artery ligation probed 
with the A2BAR antibody. A prominent band under 50 kDa was observed in all of the studies along with a 
secondary band near 37 kDa in some instances. The larger band just under 50 kDa was used for quantification. 
After quantification of A2BAR protein, membranes were probed for beta actin, which was not different in left 
and right lungs. Beta actin was used to normalize A2BAR immunoreactivity for protein loading. Ischemic left 
lungs exhibited increased A2BAR immunoreactivity compared to their control right lung counterparts. 4b. 
Representative images from studies similar to those in Figure 4a except that homogenates were obtained from 
lungs of SS rather than SD rats. Again, increased A2BAR immunoreactivity in ischemic left compared to 
contralateral right lungs was observed seven days after ischemia. 4c. Representative Western blots from the 
same samples as Figure 4a (SD rats) probed with primary A2AAR antibodies. The band between 37 and 50 kDa 
was quantified.[20] Bands were less consistent than those probed A2BAR antibody and no differences in A2AAR 
immunoreactivity between ischemic and contralateral lungs were observed. 
 Graph: Figure 5. Graph shows averaged density of A2BAR immunoreactivity normalized to beta actin in lung 
homogenates from left and right lungs of SD rats at 2 (n = 6) and 7 days (n = 8) after ischemia, and in SS rats 
seven days (n = 6) after the same ischemic injury. These are aggregate data including those examples shown in 
Figure 4. "N's in the bars represent the number of paired samples on each group. In each case, the density of 
immunoreactivity is increased in ischemic left over contralateral right lungs with p < 0.005 by paired t test. Bars 
represent standard deviation. 
Expression of the A2BAR is reported to be modulated by miRNAs 27a-3p, 27b-3p, and 128-3p.[14] RT-qPCR data 
normalized for an internal miRNA, miR191-5p demonstrated decreased 27a and 27b miRNA in ischemic versus 
nonischemic lung tissue at 7 days (Table 2). Normalization for the spiked sequence UniSP6 also showed 
decreased 27a-3p miRNA in ischemic lungs compared to contralateral controls. There was no difference in 
miR191-5p expression when normalized to UniSP6. These results confirm a decrease in miR27a-3p after 
ischemia. 
Table 2. qPCR and p-values for miR27b-3p, miR128-3p, miR27a-3p, and miR191-5p normalized to either 191-5p 
or UniSP6 for left and right lungs harvested 7 days after ischemia. Once normalized for 191-5p or UniSP6, qPCR 
values for right lung (nonischemic) were set at 1, the left lung values expressed as a fraction of the right. P-
values are different in left and right lungs for miR27b-3p and miR27a-3p when qPCR values are normalized to 
miR191, and for miR27a when normalized for UniSP6. 
 
Normalized by Nonischemic R (n = 8) mean ± SD Ischemic L (n = 8) mean ± SD Sig by t test 
miR 27b-3p miR191 1 ± 0.11 0.82 ± 0.17 *P = 0.021 
miR 128-3p miR191 1 ± 0.28 0.68 ± 0.26 P = 0.976 
miR 27a miR191 1 ± 0.17 0.66 ± 0.07 *P = 0.000135 
miR191-5p SP6 1 ± 0.12 1.04 ± 0.17 P = 0.610 
miR 27b-3p SP6 1 ± 0.08 0.86 ± 0.23 P = 0.113 
miR 128-3p SP6 1 ± 0.09 0.97 ± 0.11 P = 0.551 
miR 27a SP6 1 ± 0.1 0.7 ± 0.13 *P = 0.00014 
Histology 
We have reported that unilateral ischemia of the lung induced by pulmonary artery tie results in BOOP and 
inflammatory changes seven days after surgery in SD rats.[ 6] To begin to test the contribution of A2BAR 
expression to the development of BOOP, we quantified percent BOOP in ischemic lungs of a genetically modified 
rat strain with deletions of A2BAR relative to the background strain (Dahl SS).[22] Representative images of cross 
sections of whole mount ischemic lungs appear in Figure 6(a–c). We observed more lung involvement by BOOP 
in rats genetically modified by Adora2b disruption (Table 3 and Figure 6a–d). Additional studies to assess for 
injury were completed. Higher epithelial and inflammatory but not fibrotic scores were assigned to images of 
lung cross sections from Adora2b disrupted rats (Table 3). Pulmonary vascular changes (thickened media or 
intima) were not different between Adora2b mutant rats and background controls (Table 3). Scattered pockets 
of necrosis were observed in one of five and one of four cross sectional areas, respectively, of a SS control rat 
and an Adora2b rat (also not different and not shown). 
 
Graph: Figure 6. Representative histological images from lung cross sections from SS (a and c) and SS-AdorA2b 
mutant rats (b and d) seven days after ischemia. Low power (a and b) shows areas of increased cellularity, which 
were consistent with BOOP under high power magnification (c and d). The area of BOOP is modestly larger in the 
image from lungs of mutant rats. The green arrows in the magnified images (c and d) show typical epithelial 
changes, whereas the red arrow shows perivascular inflammation (c). In some images from mutants (not 
shown), areas of inflammation outside sections showing significant epithelioid changes were observed. 
Table 3. Mean and SEM as well as median and 95% confidence interval values for epithelial, inflammation, and 
fibrosis changes in images from lungs scored by investigators blinded to the treatment group. Epithelial and 
inflammatory changes were different in ischemic lungs of SS and SS-Adora2b mutant rats while fibrotic changes 
were not. Confidence intervals: CI and standard error of the mean: SEM. 
 
Dahl SS (n = 5) A2bAR knock out (n = 4) P-value relative to Dahl SS 
%BOOP 
   
 Mean/median 18/25 60/67.5 0.02* 
 SEM/Cl 3.4/19 10/32 
 
Epithelial 
   
 Mean/median 1.08/1.00 1.6/2.0 0.031* 
 SEM/Cl 0.15/0.3 0.18/0.39 
 
Inflammation 
   
 Mean/median 1.5/2.0 2.43/2.0 0.048* 
 SEM/Cl 0.19/0.43 0.21/0.44 
 
Fibrosis 
   
 Mean/median 0.79/1.0 1.32/2.0 0.5 ns 
 SEM/Cl 0.19/0.42 0.26/0.55 
 
Vascular changes 
   
 Mean/median 0.2/0.0 0.5/0.5 0.4 ns 
 SEM/Cl 0.5/0.55 0.29/0.92 
 
Discussion 
We provide compelling evidence that expression of A2BAR mRNA and/or protein is increased in the lungs of two 
different rat strains (SD and SS) for at least seven days following ischemia by either isolated pulmonary artery 
ligation or hilar ligation (no ventilation or perfusion) with ischemia/reperfusion. Coincident with increased A2BAR 
expression, a candidate miRNA for at least one of three sequences reported to suppress AdorA2BA transcription, 
miR27a, is decreased. Physiologically, we observed increased adenosine levels in bronchoalveolar lavage fluid 
and increased BOOP in ischemic lungs from rat strains that contain mutations in Adora2b. Collectively, these 
findings indicate that adenosine signaling via the A2BAR may mediate a protective role in ischemia-induced 
BOOP. 
Adenosine and its receptors have an established modulatory role during acute organ injury as well as during 
tissue remodeling that occur during chronic inflammatory states. Extracellular adenosine elicits biological effects 
through activation of four G-coupled protein adenosine receptors (A1AR, A2AAR, A2BAR, and A3AR).[23] In the 
lung, A2BAR expression has been reported in bronchial epithelial cells in both medium and large airways, 
pulmonary vascular cells, and alveolar macrophages.[24], [25] A major site of A2BAR translation is the type II 
alveolar epithelial cell.[24] Endogenous adenosine released following cell injury has been reported to protect 
against I/R injury in lungs.[26] Further, protection from I/R in isolated perfused rabbit lungs is achieved with 
treatment by agonists for A1, A2A, or A3 adenosine receptors.[27] In these models, decreased elaboration of the 
proinflammatory cytokine, TNF-α, and decreased neutrophil sequestration are postulated to contribute to the 
overall improvement in pulmonary function, a signaling pathway triggered by adenosine receptor binding. 
Koeppen et al. report that A2BAR activation requires higher ligand concentrations as compared to other 
adenosine receptors.[ 7] Given the abundance of adenosine during I/R and induction of A2BAR expression, 
signaling by this pathway likely promotes homeostasis. We propose that this compensatory mechanism serves 
an important role to protect the lung tissue from remodeling to a state of BOOP. 
While some studies demonstrate a protective role by A2AAR signaling during lung injury[27], [28], [29], [30] we 
did not detect changes in expression of this important adenosine receptor subtype in our studies following 
unilateral lung ischemia. A2BAR expression, however, increases over time after ischemia and I/R (Figures 3 and 
5). This result implicates A2BAR expression as an inducible and adaptive response to ischemia. Notably, a binding 
site for hypoxia-inducible factor-1α (HIF-1α) exists within the A2BAR promoter.[31], [32], [33] 
The role of A2BAR signaling in all cause injury is controversial. On the side of promoting injury, A2BAR stimulation 
has been reported to promote the development of BO in a heterotopic tracheal implantation mouse model by 
inhibiting CD4+/CD25+/Foxp3+ regulatory T cell infiltration.[ 9] In the presence of hypoxia, A2BAR activation 
synergistically activates human fibroblasts, presumably leading to fibrosis.[32] Activation of A2BAR in smooth 
bronchial muscle cells enhances release of IL-6 and monocyte chemotactic protein (MCP-1).[34] A2BAR 
transcriptionally activates HIF-1α and hence favors an ischemic response.[ 7] Most germane to the present 
studies, disruption of the A2b adenosine receptor in the rats used for our studies is associated with increased 
body weight, delayed glucose clearance, modestly elevated systemic blood pressures with age, and reduced 
cytokine production after challenge with lipopolysaccharide.[22] These data would suggest increased 
inflammatory responses evoked by ischemia in our genetically modified rats are either mediated by different 
cytokines than those evoked by LPS, or is driven largely by noncytokine dependent signaling. 
Several other models demonstrate protection with A2BAR activation. Pharmacologic inhibition and/or genetic 
elimination of A2BAR increases murine endotoxin-induced lung injury.[12] In a murine model of LPS-induced lung 
injury, activation of A2BAR on pulmonary endothelial cells decreases microvascular permeability and neutrophil 
migration into alveolar spaces.[35] A2BAR-deficient mice enjoy greater survival than their wild-type counterparts 
in polymicrobial sepsis.[36] A2BAR signaling enhances amiloride-sensitive fluid transport and elevation of 
pulmonary cAMP levels following ventilator associated lung injury in mice, suggesting that A2BAR agonist 
treatment protects by facilitating fluid resorption from the lungs.[10] Perhaps most applicable to our data, 
ischemia reperfusion injury to the liver in mice is associated with robust induction of A2BAR transcript and 
protein.[37] Mice with AdorA2BA-deletion exhibited increased sensitivity to injury. Finally, treatment of wild-
type mice with an A2BAR-selective antagonist resulted in worsened liver injury, whereas A2BAR-agonist treatment 
attenuated hepatic injury in wild type, but not in AdorA2BA−/− mice. Our data demonstrating increased BOOP 
7 days after ischemia in AdorA2BA mutant rats add additional credence to a protective role for the adenosine/ 
A2BAR signaling axis after ischemia. To our knowledge, this is the first report that A2BAR signaling is protective 
from BOOP after ischemic injury in the lung. 
Micro RNA (miRNA) are short (20–30 nucleotide) translational regulator sequences encoded in the eukaryotic 
DNA genome. Their usual function is to bind complementary single-stranded mRNA sequences undergoing 
translation by ribosomal complexes. When this binding occurs, the ribosomal translation is halted, resulting in 
an ineffective protein product. At least two miRNAs have been reported to modulate posttranscriptional 
expression of A2BAR in a model of mouse colitis: miR27b, miR128a.[14] These miRNAs decrease A2BAR translation 
in colonocytes from this model. Furthermore, miR27b and miR128a transcription was suppressed by TNF-α.[14] 
Our data demonstrate decreases in miR27a and 27b, consistent with the hypothesis that these miRNA 
contribute to post-transcriptional increase of A2BAR after injury. Further studies will help determine the 
factors/cytokines that are induced by ischemia to regulate miRNA expression, especially downregulation of 
miR27a. 
There are limitations to our studies. First, the cellular sources of increased A2BAR expression in ischemic lungs 
remain to be determined. Unfortunately, attempts at immunohistochemical localization were unsuccessful due 
to interference by background staining. Second, the specificity of commercially available antibodies for 
adenosine receptors has been questioned raising concerns regarding accuracy of assessing changes in adenosine 
receptor protein expression by immunological approaches. Nevertheless, we followed procedures utilized 
successfully in several previously published reports.[ 7], [20], [36], [37] With this in mind, it was important that 
changes in A2BAR protein expression in lung tissue observed in our studies by Western immunoblotting were 
paralleled by changes in mRNA expression. Although we did not obtain evidence for increased A2AAR expression, 
our data do not exclude a role for adenosine signaling through these or other adenosine receptor subtype 
during ischemia-induced BOOP. They do suggest, however, that increases in A2AAR expression and cross-
reactivity with A2bR do not account for the increases in A2bR protein we observed in ischemic lungs. Lastly, the 
effects seen may be due to other factors besides tissue oxidative state (e.g., resulting from hemostasis in the 
pulmonary circulation and resultant proinflammatory changes in the endothelium). 
Our work provides strong justification for additional studies. If A2BAR signaling protects from ischemic lung 
injury, then this axis affords a target to diminish the morbidity and mortality resulting from lung 
transplantation.[ 1], [ 2] Given the ∼50% 5-year mortality from BO in transplanted lungs and the extensive 
waiting lists for those with end-stage lung disease,[38], [39], [40] interventions that may extend the survival of 
transplanted lung recipients by even a few years with good functional capacity are highly desirable. Successful 
therapies will most likely be based on countering mechanisms of injury or enhancing protective signaling 
pathways. Our work provides justification for further studies of A2BAR-mediated events as a strategy to enhance 
protection of ischemic lungs. 
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